Organon & Co
NYSE:OGN

Watchlist Manager
Organon & Co Logo
Organon & Co
NYSE:OGN
Watchlist
Price: 7.85 USD 5.51% Market Closed
Market Cap: 2B USD

Organon & Co
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Organon & Co
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Organon & Co
NYSE:OGN
Net Issuance of Debt
-$49m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Issuance of Debt
$9.1B
CAGR 3-Years
287%
CAGR 5-Years
3%
CAGR 10-Years
6%
Bristol-Myers Squibb Co
NYSE:BMY
Net Issuance of Debt
-$846m
CAGR 3-Years
47%
CAGR 5-Years
14%
CAGR 10-Years
-7%
Pfizer Inc
NYSE:PFE
Net Issuance of Debt
-$5.9B
CAGR 3-Years
-41%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Net Issuance of Debt
$3B
CAGR 3-Years
-13%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Net Issuance of Debt
$11.1B
CAGR 3-Years
296%
CAGR 5-Years
76%
CAGR 10-Years
18%
No Stocks Found

Organon & Co
Glance View

In the corporate realm of healthcare, Organon & Co. emerged as a dedicated player with a mission to address vital needs in women's health. Born from a spin-off of Merck & Co.'s women's health, biosimilars, and established brands business in 2021, Organon positions itself at the heart of a neglected niche ripe with opportunity. The company's vision is clear: to enhance the health and well-being of women at every stage of life. Organon leverages its legacy of trusted brands while simultaneously developing new and innovative solutions that cater to female-specific health concerns. Through its robust portfolio of medicines and products, Organon focuses on conditions that resonate deeply with women's health issues, from contraception and fertility to postpartum recovery. As a biopharmaceutical company, it prides itself on combining a blend of established and emerging solutions to create sustainable value. Organon’s business model capitalizes on its diverse range of offerings, employing a three-pronged strategy. The women's health segment is a significant focus, providing products that are central in addressing previously unmet needs. Meanwhile, the biosimilars segment expands the company's reach, offering affordable alternatives to more costly biologic treatments, which is increasingly crucial in today's price-sensitive healthcare environment. Lastly, the established brands division comprises a portfolio of mature pharmaceutical products that continue to generate stable revenue, thanks partly to their enduring trust among healthcare professionals. This multifaceted approach ensures Organon isn't merely reliant on new product development but can also maximize value from existing assets. The synergy across these divisions allows Organon to not only meet current market demands but also anticipate future health trends, making it a dynamic entity in the global healthcare landscape.

OGN Intrinsic Value
51.99 USD
Undervaluation 85%
Intrinsic Value
Price

See Also

What is Organon & Co's Net Issuance of Debt?
Net Issuance of Debt
-49m USD

Based on the financial report for Dec 31, 2024, Organon & Co's Net Issuance of Debt amounts to -49m USD.

What is Organon & Co's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 1Y
81%

Over the last year, the Net Issuance of Debt growth was 81%.

Back to Top